Search

News Recent Advances in Physiotherapy for Hemophiliacs

Physiotherapy specifically focuses on movement and the movement potential of the individual, with the purpose of restoring or maintaining maximum mobility and functional abilities throughout life. Numerous experiences have shown that physiotherapeutic procedures hold a key position for patients with hemophilia.

Source: Hemophilia with Movement 28. 1. 2021

News Transition of Hemophilia A Patients with a History of Coagulation Factor Inhibitor to Emicizumab

During the World Federation of Hemophilia (WFH) conference, held virtually in June 2020, interesting results were presented for patients with Hemophilia A who had a history of FVIII inhibitor and are now using Emicizumab.

Source: Quality Life Even with Hemophilia 3. 8. 2020

News Brentuximab Vedotin as Another Therapeutic Option in Cutaneous T-Cell Lymphoma

Current systemic treatment for patients with cutaneous T-cell lymphoma (CTCL) unfortunately has limited efficacy, achieving low response rates and short-lasting remissions. Moreover, there is no curative therapy modality for advanced stages of CTCL. However, the results of the recently concluded ALCANZA clinical trial indicate the potential of brentuximab vedotin in this indication.

Source: Hematologic Malignancies 4. 1. 2022

News Use of Enoxaparin in Patients After Implantation of Left Ventricular Assist Device

Left ventricular assist devices (LVAD) are utilized in patients with end-stage heart failure (HF). Warfarin is typically employed for long-term anticoagulation, but there are no standardized recommendations for anticoagulant therapy during the postoperative period. One option to bridge the time until therapeutic INR is achieved after LVAD implantation is the low molecular weight heparin (LMWH) enoxaparin, which was investigated for its efficacy and safety in this indication by experts from Kansas, USA, cited in the following study.

Source: Thromboprophylaxis 28. 11. 2023

News New Solution for Moderate Incontinence –⁠ Discreet Pull-Up Diaper Pants

The range of products for people with incontinence is constantly expanding –⁠ recent additions include pull-up diaper pants labeled Seni Active Basic and Seni Active Classic.

Source: Incontinence 30. 8. 2022

News Romiplostim in a Pregnant Woman −⁠ Case Report

The following clinical case demonstrates good control of resistant immune thrombocytopenia in a pregnant woman during the administration of romiplostim.

Source: Immune Thrombocytopenia 16. 5. 2022

News Effect of Administering Ferric Carboxymaltose on Quality of Life in Heart Failure Patients

The quality of life in patients with heart failure is significantly reduced. The concurrent occurrence of iron deficiency further exacerbates this situation. The AFFIRM-AHF study evaluated the impact of intravenous administration of ferric carboxymaltose on health-related quality of life (HRQoL) in patients with heart failure who also suffered from iron deficiency.

Source: Iron Deficiency and Anemia 7. 2. 2022

News Options for Tapering TPO-RA in ITP Patients: Practical Experience and Expert Consensus

A recently published British study aims to provide recommendations on tapering TPO-RA in patients with immune thrombocytopenia (ITP) based on existing evidence, survey results of clinical practice among hematologists, and expert consensus.

Source: Immune Thrombocytopenia 25. 10. 2022

News INFOGRAPHIC: Prevention and Management of Hypotension During Sacubitril/Valsartan Treatment

Despite the undeniable benefits of sacubitril/valsartan in terms of morbidity and mortality in patients with chronic heart failure, its administration can be complicated by side effects. The most common of these is hypotension.

Source: Chronic Heart Failure and Lipidology 20. 5. 2021

News New Drug in the Biologic Therapy Arsenal for Plaque Psoriasis

Bimekizumab shows promising effects in clinical studies with psoriasis patients. Let's take a closer look at this recently approved drug in our brief summary.

Source: Psoriasis 25. 4. 2022

News Chronic Thromboembolic Pulmonary Hypertension –⁠ Editorial

Belicová M. Chronic Thromboembolic Pulmonary Hypertension in a Regional Hospital. Vnitř Lék 2011; 57(2): 140–146.

Source: Pulmonary hypertension (CTEPH, PAH) 21. 2. 2020

News Modern Physical Therapy for Hemophiliacs

Today's physical therapists working with hemophiliacs find themselves in a unique situation -⁠ far more effective treatments are available than in past years, leading to a better quality of life. However, it remains necessary to carefully consider what may still have harmful or positive effects on joint health. Dr. Sebastien Lobet from Cliniques universitaires Saint-Luc in Brussels reflected on joint health, sports, and physical therapy in relation to modern treatment for hemophiliacs during the 9th Hemophilia Academy, held online from October 5 to 7.

Source: Hemophilia with Movement 7. 12. 2021

News Options for Reducing or Discontinuing TPO-RA Therapy in ITP Patients −⁠ Expert Consensus

There are currently no clear recommendations regarding dose reduction or discontinuation of thrombopoietin receptor agonists (TPO-RA) in patients with immune thrombocytopenia (ITP). A consensus by British authors offers insights into current clinical practice and the related issues.

Source: Immune Thrombocytopenia 20. 5. 2021

News Finding Balance Between Intracranial Efficacy and Adverse Effects of ALK Kinase Inhibition

More than 7 years –⁠ that is the current median survival of patients with non-small cell lung cancer (NSCLC) with a mutation in the anaplastic lymphoma kinase (ALK) gene who are receiving targeted therapy. Therefore, the quality of life of patients on treatment and the search for a balance between its antitumor efficacy and adverse effects (AEs) is becoming the focus of clinical research. Recently, lorlatinib has been discussed in this context.

Source: Genetic Profile and Treatment of NSCLC 6. 12. 2022

News From Hell to the Light at the End of the Tunnel –⁠ A Task for Eletriptan

In recent months, under the spotlight of new biological treatments, the focus has been predominantly on the prophylactic treatment of migraines. However, we should not forget about acute therapy. In this indication, the pharmacological group of triptans is dominant. So, does eletriptan reliably stop the hell named a migraine attack? And is the response to this drug consistent?

Source: Treatment of Severe Migraine 4. 1. 2022